Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Announces Earnings Results

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) posted its earnings results on Tuesday. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02), Zacks reports. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The firm had revenue of $11.25 billion for the quarter, compared to analyst estimates of $11.21 billion.

Bayer Aktiengesellschaft Trading Up 3.3%

OTCMKTS:BAYRY opened at $14.41 on Wednesday. The stock has a market cap of $56.63 billion, a price-to-earnings ratio of 9.76, a PEG ratio of 2.11 and a beta of 0.57. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. Bayer Aktiengesellschaft has a 1 year low of $7.48 and a 1 year high of $15.23. The business has a fifty day moving average of $13.43 and a 200-day moving average of $12.56.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy”.

Key Bayer Aktiengesellschaft News

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: Bayer raised its 2026 profit outlook as demand for key medicines, including Nubeqa and Kerendia, supported a recovery in pharmaceuticals and lifted EBITDA guidance. The improvement helped offset pressures in agriculture and consumer health. Bayer raises 2026 profit outlook
• Positive Sentiment: The company is seeking a larger role in Latin America’s fast-growing biologicals market, offering a potential growth opportunity, though the financial impact was not specified. Bayer seeks bigger role in Latin American biologicals market
• Neutral Sentiment: Bayer will present new cardiovascular, kidney and stroke data at the American Heart Association’s scientific sessions. The presentations could provide pipeline updates, but the announced data have not yet established a commercial or clinical benefit. Bayer to present new data at AHA sessions
• Negative Sentiment: Third-quarter EPS was $0.11, below the $0.13 analyst consensus. Revenue of $11.25 billion slightly topped estimates, but the earnings miss remains a near-term concern. BAYRY Q3 earnings and revenues miss estimates
• Negative Sentiment: Despite the better outlook, analysts and the earnings-call coverage characterize Bayer as needing to demonstrate that the recovery can persist; pressures outside pharmaceuticals and other ongoing risks remain. Bayer earnings call signals growth amid ongoing risks

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies.